Compare Stocks: NERV, GLAS, CRMD, and AQST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.55 +2.5%	$4.59	$2.93 ▼ $7.55	$557.27M	1.49	2.24 million shs	2.27 million shs
CRMD CorMedix	$7.19 -3.1%	$7.87	$6.13 ▼ $13.02	$578.35M	1.4	812,982 shs	1.13 million shs
GLAS Glass House Brands	$5.45 +2.5%	$8.76	$4.97 ▼ $13.93	$499.02M	N/A	1.23 million shs	1.41 million shs
NERV Minerva Neurosciences	$3.28 +1.5%	$4.17	$2.08 ▼ $12.46	$154.23M	-0.1	154,200 shs	57,021 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.48%	-2.78%	-15.43%	+8.85%	-22.62%
CRMD CorMedix	-3.10%	-8.41%	-16.49%	-17.83%	-34.93%
GLAS Glass House Brands	+2.91%	-20.29%	-35.98%	-55.92%	+545,299,900.00%
NERV Minerva Neurosciences	+1.55%	-3.53%	-26.79%	-35.69%	+56.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.55 +2.5%	$4.59	$2.93 ▼ $7.55	$557.27M	1.49	2.24 million shs	2.27 million shs
CRMD CorMedix	$7.19 -3.1%	$7.87	$6.13 ▼ $13.02	$578.35M	1.4	812,982 shs	1.13 million shs
GLAS Glass House Brands	$5.45 +2.5%	$8.76	$4.97 ▼ $13.93	$499.02M	N/A	1.23 million shs	1.41 million shs
NERV Minerva Neurosciences	$3.28 +1.5%	$4.17	$2.08 ▼ $12.46	$154.23M	-0.1	154,200 shs	57,021 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+2.48%	-2.78%	-15.43%	+8.85%	-22.62%
CRMD CorMedix	-3.10%	-8.41%	-16.49%	-17.83%	-34.93%
GLAS Glass House Brands	+2.91%	-20.29%	-35.98%	-55.92%	+545,299,900.00%
NERV Minerva Neurosciences	+1.55%	-3.53%	-26.79%	-35.69%	+56.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$9.17	101.47% Upside
CRMD CorMedix	2.78	Moderate Buy	$15.00	108.62% Upside
GLAS Glass House Brands	2.00	Hold	$16.00	193.42% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	215.04% Upside

Current Analyst Ratings Breakdown

Latest NERV, GLAS, CRMD, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRMD CorMedix	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/11/2026	GLAS Glass House Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/20/2026	GLAS Glass House Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	GLAS Glass House Brands	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.09M	10.56	N/A	N/A	($0.28) per share	-16.25
CRMD CorMedix	$311.71M	1.80	$1.98 per share	3.63	$5.14 per share	1.40
GLAS Glass House Brands	$176.98M	2.89	N/A	N/A	N/A	∞
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
CRMD CorMedix	$163.05M	$2.14	3.36	51.36	1.37	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
GLAS Glass House Brands	N/A	N/A	N/A	27.27	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)

Latest NERV, GLAS, CRMD, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
CRMD CorMedix	0.31	2.56	2.36
GLAS Glass House Brands	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	20.15	20.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CRMD CorMedix	34.18%
GLAS Glass House Brands	N/A
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
CRMD CorMedix	3.50%
GLAS Glass House Brands	N/A
NERV Minerva Neurosciences	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
CRMD CorMedix	191	77.94 million	75.22 million	Optionable
GLAS Glass House Brands	357	93.80 million	N/A	N/A
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable

NERV, GLAS, CRMD, and AQST Headlines

Recent News About These Companies

Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Analysts

October 3 at 6:13 AM | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

October 2 at 3:01 AM | americanbankingnews.com

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average - Here's Why

October 2 at 2:59 AM | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200-Day Moving Average - Here's Why

September 16, 2026 | marketbeat.com

Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Brokerages

September 8, 2026 | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200-Day Moving Average - Here's What Happened

September 4, 2026 | marketbeat.com

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

August 28, 2026 | globenewswire.com

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

August 7, 2026 | globenewswire.com

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

June 1, 2026 | globenewswire.com

Minerva Neurosciences Launches ATM Offering to Fund Trial

May 27, 2026 | tipranks.com

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

May 20, 2026 | zacks.com

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026 | globenewswire.com

Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | finanznachrichten.de

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | globenewswire.com

Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69

April 28, 2026 | msn.com

Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation

April 16, 2026 | msn.com

Minerva launched with New Outperform at Citizens on schizophrenia candidate

April 15, 2026 | seekingalpha.com

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

April 6, 2026 | tipranks.com

Minerva Announces Leadership Transition

April 2, 2026 | globenewswire.com

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

March 31, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NERV, GLAS, CRMD, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.55 +0.11 (+2.48%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.52 -0.03 (-0.66%)

As of 10/2/2026 07:39 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

CorMedix NASDAQ:CRMD

$7.19 -0.23 (-3.10%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.32 +0.14 (+1.88%)

As of 10/2/2026 07:30 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Glass House Brands NYSE:GLAS

$5.45 +0.13 (+2.50%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$5.47 +0.02 (+0.31%)

As of 10/2/2026 07:55 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Minerva Neurosciences NASDAQ:NERV

$3.28 +0.05 (+1.55%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.27 -0.01 (-0.30%)

As of 10/2/2026 07:30 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, GLAS, CRMD, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, GLAS, CRMD, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, GLAS, CRMD, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, GLAS, CRMD, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

CorMedix NASDAQ:CRMD

Glass House Brands NYSE:GLAS

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, GLAS, CRMD, and AQST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, GLAS, CRMD, and AQST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, GLAS, CRMD, and AQST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, GLAS, CRMD, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

CorMedix NASDAQ:CRMD

Glass House Brands NYSE:GLAS

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools